Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,531.06 +22.05 (+0.40%) Dow
39,277.23 -54.62 (-0.14%) Nasdaq
18,170.26 +141.50 (+0.78%) Bitcoin USD
60,348.24 -1,452.80 (-2.35%) CMC Crypto 200
1,297.15 -37.76 (-2.83%)
BNGO Feb 2025 1.000 call
| Previous close | 0.1400 |
| Open | 0.1500 |
| Bid | 0.1000 |
| Ask | 0.1500 |
| Strike | 1.00 |
| Expiry date | 2025-02-21 |
| Day's range | 0.1400 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireBionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applicationsTwo scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing applications will be presented at the conference SAN DIEGO, July 02, 2024 (GLO
- GlobeNewswire
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflowVIA is expected to enhance Revvity’s newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow’s interpretation capabilities SAN DIEGO, June 20, 2024 (G
GlobeNewswireBionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in
